Document Type : Original Article

Authors

1 Department of Internal Medicine, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran

2 Pediatric Digestive and Hepatic Diseases Research Center, Zabol University of Medical Sciences, Zabol, Iran

3 Forensic Medicine and Toxicology, Zabol University of Medical Science, Zabol, Iran

Abstract

Although liver biopsy is a gold standard for evaluating liver fibrosis, due to the invasive nature of the biopsy and complications related to it in thalassemia major patients, it is important to use new, valid and non-invasive methods to estimate the stage of liver fibrosis. Therefore, this study aimed to evaluate the status of non-invasive liver parameters such as FIB-4, APRI, and AAR in thalassemia major patients. The present descriptive-analytical study was conducted in 2019 on patients with thalassemia major. In this study, 140 thalassemia patients were evaluated for demographic findings, liver enzymes and non-invasive indicators of liver fibrosis. Also, underlying diseases such as diabetes, ischemic heart disease and other cases were extracted from patients' medical records. Finally, the data were entered into SPSS V20 software and evaluated. In the present study, 38.6% of the patients were male and the mean age of the patients was 18.47 ± 8.21 years with an age range of 1 to 37 years. Evidence from the present study indicated that patients with thalassemia who had an abnormal liver echo had a significantly higher abnormal APRI index that was consistent with an abnormal liver echo (P = 0.019). However, these items are not applicable for AAR and FIB-4 indicators (P˃0.05). The correlation coefficient of APRI and AAR indices with ALT, AST and ferritin was relatively high and was statistically significant (P˂0.05). Therefore, it can be concluded that these enzymes are well associated with changes in these indices, while there was no significant correlation between the ALKP enzyme and the above indicators. The evidence of the present study showed that non-invasive tests for liver fibrosis including APRI and AAR can have a suitable substitute in assessing the progression of liver fibrosis in thalassemia patients.

Graphical Abstract

Investigation of non-invasive indicators of liver fibrosis in thalassemia major patients

Keywords

Main Subjects

Selected author of this article by journal

ِDr. Khdije Saravai
Zabol University of Medical Sciences

ORCID

Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/

 

Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.

 

Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 15%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected], [email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.

[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.

[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.

[3] There is no limit to the number of words in a letter.

[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.

[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments.

[7] Letters will be answered as soon as possible.

  1. Omar A, Gendy W, Marzouk I, Wagdy M (2005) Molecular basis of beta-thalassemia in Alexandria. The Egyptian Journal of Immunology 12 (1): 15-24. doi: https://doi.org/10.1101/cshperspect.a011700
  2. Ghavamzadeh A, Mirzania M, Kamalian N, Sedighi N, Azimi P (2015) Hepatic iron overload and fibrosis in patients with beta thalassemia major after hematopoietic stem cell transplantation: a pilot study. International Journal of Hematology-Oncology and Stem Cell Research 9 (2): 55-59. doi: https://pubmed.ncbi.nlm.nih.gov/25922644
  3. Bayanzay K, Alzoebie L (2016) Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. Journal of blood medicine 2016 (7): 159-169. doi: https:///doi.org/10.2147/JBM.S61540
  4. Coates TD, Carson S, Wood JC, Berdoukas V (2016) Management of iron overload in hemoglobinopathies: what is the appropriate target iron level? Annals of the New York Academy of Sciences 1368 (1): 95-106. doi: https://doi.org/10.1111/nyas.13060
  5. Kwiatkowski JL (2016) Current recommendations for chelation for transfusion‐dependent thalassemia. Annals of the New York Academy of Sciences 1368 (1): 107-114. doi: https://doi.org/10.1111/nyas.13088
  6. Oikonomidou PR, Casu C, Rivella S (2016) New strategies to target iron metabolism for the treatment of beta thalassemia. Annals of the New York Academy of Sciences 1368 (1): 162-168. doi: https://doi.org/10.1111/nyas.13018
  7. Maurer HS, Lloyd-Still JD, Ingrisano C, Gonzalez-Crussi F, Honig GR (1988) A prospective evaluation of iron chelation therapy in children with severe β-thalassemia: a six-year study. American Journal of Diseases of Children 142 (3): 287-292. doi: https://doi.org/10.1001/archpedi.1988.02150030057020
  8. Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (4): 1147-1171. doi: https://doi.org/10.1002/hep.20119
  9. Yoon JH, Lee JM, Woo HS, Yu MH, Joo I, Lee ES, Sohn JY, Lee KB, Han JK, Choi BI (2013) Staging of hepatic fibrosis: comparison of magnetic resonance elastography and shear wave elastography in the same individuals. Korean Journal of Radiology 14 (2): 202-212. doi: https://doi.org/10.3348/kjr.2013.14.2.202
  10. Group FMCS, Bedossa P (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20 (1): 15-20. doi: https://doi.org/10.1002/hep.1840200104
  11. Sebastiani G, Alberti A (2012) How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? Journal of viral hepatitis 19: 18-32. doi: https://doi.org/10.1111/j.1365-2893.2011.01518.x
  12. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE (2005) Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41 (6): 1376-1382. doi: https://doi.org/10.1002/hep.20717
  13. Ding D, Li H, Liu P, Chen L, Kang J, Zhang Y, Ma D, Chen Y, Luo J, Meng Z (2015) FibroScan, aspartate aminotransferase and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factor (FIB-4), and their combinations in the assessment of liver fibrosis in patients with hepatitis B. International Journal of Clinical and Experimental Medicine 8 (11): 20876-20882. doi: https://pubmed.ncbi.nlm.nih.gov/26885013
  14. Beime J, Krech T, Hischke S, Grabhorn E, Brinkert F (2019) Tissue inhibitor of metalloproteinase 1 and AST‐to‐Platelet Ratio Index as noninvasive biomarkers predict allograft fibrosis after pediatric liver transplantation. Clinical Transplantation 33 (10): e13676. doi: https://doi.org/10.1111/ctr.13676
  15. Peleg N, Issachar A, Sneh-Arbib O, Shlomai A (2017) AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease 49 (10): 1133-1138. doi: https://doi.org/10.1016/j.dld.2017.05.002
  16. D'Souza RS, Neves Souza L, Isted A, Fitzpatrick E, Vimalesvaran S, Cotoi C, Amin S, Heaton N, Quaglia A, Dhawan A (2016) AST‐to‐platelet ratio index in non‐invasive assessment of long‐term graft fibrosis following pediatric liver transplantation. Pediatric Transplantation 20 (2): 222-226. doi: https://doi.org/10.1111/petr.12661
  17. Jafarov F, Kaya E, Bakir A, Eren F, Yilmaz Y (2020) The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. European Journal of Gastroenterology & Hepatology 32 (5): 642-649. doi: https://doi.org/10.1097/MEG.0000000000001573
  18. Turner BJ, Liang Y, Singal AG (2017) FIB-4 and imaging for measuring fibrosis in hepatitis C virus. European Journal of Gastroenterology & Hepatology 29 (2): 192-198. doi: https://doi.org/10.1097/MEG.0000000000000766
  19. Deng H, Qi X, Guo X (2015) Diagnostic accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex scores in predicting the presence of esophageal varices in liver cirrhosis: a systematic review and meta-analysis. Medicine 94 (42): e1795. doi: https://doi.org/10.1097%2FMD.0000000000001795
  20. Elesawy BH, Abd El Hafez A, Dorgham LS, El-Askary A (2014) Limited reliability of five non-invasive biomarkers in predicting hepatic fibrosis in chronic HCV mono-infected patients opposed to METAVIR scoring. Pathology, research and practice 210 (12): 922-928. doi: https://doi.org/10.1016/j.prp.2014.07.005
  21. Kliemann DA, Wolff FH, Tovo CV, Alencastro PR, Ikeda ML, Brandao AB, Barcellos N, Fuchs SC (2016) Biochemical non-invasive assessment of liver fibrosis cannot replace biopsy in HIV-HCV coinfected patients. Ann Hepatol 15 (1): 27-32. doi: https://doi.org/10.5604/16652681.1184197
  22. Ragazzo TG, Paranagua-Vezozzo D, Lima FR, de Campos Mazo DF, Pessoa MG, Oliveira CP, Alves VAF, Carrilho FJ (2017) Accuracy of transient elastography-FibroScan(R), acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. Clinics (Sao Paulo, Brazil) 72 (9): 516-525. doi: https://doi.org/10.6061/clinics/2017(09)01
  23. Zhang XY, Qian J, Li P, Hu LH, Mi YQ (2018) Clinical value of noninvasive method in diagnosing hepatic fibrosis about chronic HBV carriers. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 26 (5): 332-336. doi: https://doi.org/10.3760/cma.j.issn.1007-3418.2018.05.004
  24. Hamidieh AA, Shazad B, Ostovaneh MR, Behfar M, Tayebi S, Malekzadeh R, Ghavamzadeh A, Poustchi H (2014) Noninvasive measurement of liver fibrosis using transient elastography in pediatric patients with major thalassemia who are candidates for hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 20 (12): 1912-1917. doi: https://doi.org/10.1016/j.bbmt.2014.07.025
  25. Al-Moshary M, Imtiaz N, Al-Mussaed E, Khan A, Ahmad S, Albqami S (2020) Clinical and Biochemical Assessment of Liver Function Test and Its Correlation with Serum Ferritin Levels in Transfusion-dependent Thalassemia Patients. Cureus 12 (4): e7574. doi: https://doi.org/10.7759/cureus.7574
  26. Hussain A, Gul MA, Khalid MU (2019) Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan). BMJ Open Gastroenterol 6 (1): e000316. doi: https://doi.org/10.1136/bmjgast-2019-000316
  27. Resnick E, Shteingart S, Melamud B, Bdolah-Abram T, Zalut T, Reuben A, Lurie Y (2016) Enzyme pattern of biliary colic: A counterintuitive picture. World journal of hepatology 8 (36): 1629-1636. doi: https://doi.org/10.4254/wjh.v8.i36.1629
  28. Wei L, Ye Z, Bao Z, Xu X, Lin X, Chen L (2020) Application of acoustic radiation force impulse elastography combined with serum markers in Child-Pugh grading. Clinics (Sao Paulo, Brazil) 75: e1670. doi: https://doi.org/10.6061/clinics/2020/e1670
  29. Poustchi H, Eslami M, Ostovaneh MR, Modabbernia A, Saeedian FS, Taslimi S, George J, Malekzadeh R, Zamani F (2013) Transient elastography in hepatitis C virus‐infected patients with beta‐thalassemia for assessment of fibrosis. Hepatology research 43 (12): 1276-1283. doi: https://doi.org/10.1111/hepr.12088
  30. Elalfy MS, Esmat G, Matter RM, Aziz HEA, Massoud WA (2013) Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation. Annals of hepatology 12 (1): 54-61. doi:
  31. Papastamataki M, Delaporta P, Premetis E, Kattamis A, Ladis V, Papassotiriou I (2010) Evaluation of liver fibrosis in patients with thalassemia: the important role of hyaluronic acid. Blood Cells, Molecules, and Diseases 45 (3): 215-218. doi: https://doi.org/10.1016/j.bcmd.2010.06.002
  32. Fernandez-Yunquera A, Ripoll C, Banares R, Puerto M, Rincon D, Yepes I, Catalina V, Salcedo M (2014) Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World journal of transplantation 4 (2): 133-140. doi: https://doi.org/10.5500/wjt.v4.i2.133
  33. Nassef YE, Shady MM, Galal EM, Hamed MA (2013) Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children. Mem Inst Oswaldo Cruz 108 (7): 887-893. doi: https://doi.org/10.1590/0074-0276130139
  34. Orasan OH, Iancu M, Sava M, Saplontai-Pop A, Cozma A, Sarlea ST, Lungoci C, Ungureanu MI, Negrean V, Sampelean D, Dumitrascu DL (2015) Non-invasive assessment of liver fibrosis in chronic viral hepatitis. European journal of clinical investigation 45 (12): 1243-1251. doi: https://doi.org/10.1111/eci.12543
  35. Wang M, Liu R, Liang Y, Yang G, Huang Y, Yu C, Sun K, Lai Y, Xia Y (2017) Iron overload correlates with serum liver fibrotic markers and liver dysfunction: Potential new methods to predict iron overload-related liver fibrosis in thalassemia patients. United European Gastroenterol J 5 (1): 94-103. doi: https://doi.org/10.1177/2050640616646525